LPI (LP Information)' newest research report, the “Oral Hypoglycemic Drugs Industry Forecast” looks at past sales and reviews total world Oral Hypoglycemic Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Oral Hypoglycemic Drugs sales for 2023 through 2029. With Oral Hypoglycemic Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oral Hypoglycemic Drugs industry.
This Insight Report provides a comprehensive analysis of the global Oral Hypoglycemic Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Oral Hypoglycemic Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Oral Hypoglycemic Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oral Hypoglycemic Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oral Hypoglycemic Drugs.
The global Oral Hypoglycemic Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Oral Hypoglycemic Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Oral Hypoglycemic Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Oral Hypoglycemic Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Oral Hypoglycemic Drugs players cover Pfizer, AstraZeneca, Johnson & Johnson, GlaxoSmithKline, Merck & Co, Eli Lilly, Sanofi, Takeda Pharmaceuticals and Novo Nordisk, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Oral Hypoglycemic Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Sulfonylureas (SU)
Double Guanidine
Glucosidase Inhibitor
Insulin Synergist
Segmentation by application
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
AstraZeneca
Johnson & Johnson
GlaxoSmithKline
Merck & Co
Eli Lilly
Sanofi
Takeda Pharmaceuticals
Novo Nordisk
Servier Laboratories
Boehringer Ingelheim
Bristol-Myers Squibb
Key Questions Addressed in this Report
What is the 10-year outlook for the global Oral Hypoglycemic Drugs market?
What factors are driving Oral Hypoglycemic Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Oral Hypoglycemic Drugs market opportunities vary by end market size?
How does Oral Hypoglycemic Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Oral Hypoglycemic Drugs Annual Sales 2018-2029 2.1.2 World Current & Future Analysis for Oral Hypoglycemic Drugs by Geographic Region, 2018, 2022 & 2029 2.1.3 World Current & Future Analysis for Oral Hypoglycemic Drugs by Country/Region, 2018, 2022 & 2029 2.2 Oral Hypoglycemic Drugs Segment by Type 2.2.1 Sulfonylureas (SU) 2.2.2 Double Guanidine 2.2.3 Glucosidase Inhibitor 2.2.4 Insulin Synergist 2.3 Oral Hypoglycemic Drugs Sales by Type 2.3.1 Global Oral Hypoglycemic Drugs Sales Market Share by Type (2018-2023) 2.3.2 Global Oral Hypoglycemic Drugs Revenue and Market Share by Type (2018-2023) 2.3.3 Global Oral Hypoglycemic Drugs Sale Price by Type (2018-2023) 2.4 Oral Hypoglycemic Drugs Segment by Application 2.4.1 Hospital 2.4.2 Clinic 2.4.3 Others 2.5 Oral Hypoglycemic Drugs Sales by Application 2.5.1 Global Oral Hypoglycemic Drugs Sale Market Share by Application (2018-2023) 2.5.2 Global Oral Hypoglycemic Drugs Revenue and Market Share by Application (2018-2023) 2.5.3 Global Oral Hypoglycemic Drugs Sale Price by Application (2018-2023) 3 Global Oral Hypoglycemic Drugs by Company 3.1 Global Oral Hypoglycemic Drugs Breakdown Data by Company 3.1.1 Global Oral Hypoglycemic Drugs Annual Sales by Company (2018-2023) 3.1.2 Global Oral Hypoglycemic Drugs Sales Market Share by Company (2018-2023) 3.2 Global Oral Hypoglycemic Drugs Annual Revenue by Company (2018-2023) 3.2.1 Global Oral Hypoglycemic Drugs Revenue by Company (2018-2023) 3.2.2 Global Oral Hypoglycemic Drugs Revenue Market Share by Company (2018-2023) 3.3 Global Oral Hypoglycemic Drugs Sale Price by Company 3.4 Key Manufacturers Oral Hypoglycemic Drugs Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Oral Hypoglycemic Drugs Product Location Distribution 3.4.2 Players Oral Hypoglycemic Drugs Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023) 3.6 New Products and Potential Entrants 3.7 Mergers & Acquisitions, Expansion 4 World Historic Review for Oral Hypoglycemic Drugs by Geographic Region 4.1 World Historic Oral Hypoglycemic Drugs Market Size by Geographic Region (2018-2023) 4.1.1 Global Oral Hypoglycemic Drugs Annual Sales by Geographic Region (2018-2023) 4.1.2 Global Oral Hypoglycemic Drugs Annual Revenue by Geographic Region (2018-2023) 4.2 World Historic Oral Hypoglycemic Drugs Market Size by Country/Region (2018-2023) 4.2.1 Global Oral Hypoglycemic Drugs Annual Sales by Country/Region (2018-2023) 4.2.2 Global Oral Hypoglycemic Drugs Annual Revenue by Country/Region (2018-2023) 4.3 Americas Oral Hypoglycemic Drugs Sales Growth 4.4 APAC Oral Hypoglycemic Drugs Sales Growth 4.5 Europe Oral Hypoglycemic Drugs Sales Growth 4.6 Middle East & Africa Oral Hypoglycemic Drugs Sales Growth 5 Americas 5.1 Americas Oral Hypoglycemic Drugs Sales by Country 5.1.1 Americas Oral Hypoglycemic Drugs Sales by Country (2018-2023) 5.1.2 Americas Oral Hypoglycemic Drugs Revenue by Country (2018-2023) 5.2 Americas Oral Hypoglycemic Drugs Sales by Type 5.3 Americas Oral Hypoglycemic Drugs Sales by Application 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Oral Hypoglycemic Drugs Sales by Region 6.1.1 APAC Oral Hypoglycemic Drugs Sales by Region (2018-2023) 6.1.2 APAC Oral Hypoglycemic Drugs Revenue by Region (2018-2023) 6.2 APAC Oral Hypoglycemic Drugs Sales by Type 6.3 APAC Oral Hypoglycemic Drugs Sales by Application 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe Oral Hypoglycemic Drugs by Country 7.1.1 Europe Oral Hypoglycemic Drugs Sales by Country (2018-2023) 7.1.2 Europe Oral Hypoglycemic Drugs Revenue by Country (2018-2023) 7.2 Europe Oral Hypoglycemic Drugs Sales by Type 7.3 Europe Oral Hypoglycemic Drugs Sales by Application 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Oral Hypoglycemic Drugs by Country 8.1.1 Middle East & Africa Oral Hypoglycemic Drugs Sales by Country (2018-2023) 8.1.2 Middle East & Africa Oral Hypoglycemic Drugs Revenue by Country (2018-2023) 8.2 Middle East & Africa Oral Hypoglycemic Drugs Sales by Type 8.3 Middle East & Africa Oral Hypoglycemic Drugs Sales by Application 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of Oral Hypoglycemic Drugs 10.3 Manufacturing Process Analysis of Oral Hypoglycemic Drugs 10.4 Industry Chain Structure of Oral Hypoglycemic Drugs 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 Oral Hypoglycemic Drugs Distributors 11.3 Oral Hypoglycemic Drugs Customer 12 World Forecast Review for Oral Hypoglycemic Drugs by Geographic Region 12.1 Global Oral Hypoglycemic Drugs Market Size Forecast by Region 12.1.1 Global Oral Hypoglycemic Drugs Forecast by Region (2024-2029) 12.1.2 Global Oral Hypoglycemic Drugs Annual Revenue Forecast by Region (2024-2029) 12.2 Americas Forecast by Country 12.3 APAC Forecast by Region 12.4 Europe Forecast by Country 12.5 Middle East & Africa Forecast by Country 12.6 Global Oral Hypoglycemic Drugs Forecast by Type 12.7 Global Oral Hypoglycemic Drugs Forecast by Application 13 Key Players Analysis 13.1 Pfizer 13.1.1 Pfizer Company Information 13.1.2 Pfizer Oral Hypoglycemic Drugs Product Portfolios and Specifications 13.1.3 Pfizer Oral Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.1.4 Pfizer Main Business Overview 13.1.5 Pfizer Latest Developments 13.2 AstraZeneca 13.2.1 AstraZeneca Company Information 13.2.2 AstraZeneca Oral Hypoglycemic Drugs Product Portfolios and Specifications 13.2.3 AstraZeneca Oral Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.2.4 AstraZeneca Main Business Overview 13.2.5 AstraZeneca Latest Developments 13.3 Johnson & Johnson 13.3.1 Johnson & Johnson Company Information 13.3.2 Johnson & Johnson Oral Hypoglycemic Drugs Product Portfolios and Specifications 13.3.3 Johnson & Johnson Oral Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.3.4 Johnson & Johnson Main Business Overview 13.3.5 Johnson & Johnson Latest Developments 13.4 GlaxoSmithKline 13.4.1 GlaxoSmithKline Company Information 13.4.2 GlaxoSmithKline Oral Hypoglycemic Drugs Product Portfolios and Specifications 13.4.3 GlaxoSmithKline Oral Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.4.4 GlaxoSmithKline Main Business Overview 13.4.5 GlaxoSmithKline Latest Developments 13.5 Merck & Co 13.5.1 Merck & Co Company Information 13.5.2 Merck & Co Oral Hypoglycemic Drugs Product Portfolios and Specifications 13.5.3 Merck & Co Oral Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.5.4 Merck & Co Main Business Overview 13.5.5 Merck & Co Latest Developments 13.6 Eli Lilly 13.6.1 Eli Lilly Company Information 13.6.2 Eli Lilly Oral Hypoglycemic Drugs Product Portfolios and Specifications 13.6.3 Eli Lilly Oral Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.6.4 Eli Lilly Main Business Overview 13.6.5 Eli Lilly Latest Developments 13.7 Sanofi 13.7.1 Sanofi Company Information 13.7.2 Sanofi Oral Hypoglycemic Drugs Product Portfolios and Specifications 13.7.3 Sanofi Oral Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.7.4 Sanofi Main Business Overview 13.7.5 Sanofi Latest Developments 13.8 Takeda Pharmaceuticals 13.8.1 Takeda Pharmaceuticals Company Information 13.8.2 Takeda Pharmaceuticals Oral Hypoglycemic Drugs Product Portfolios and Specifications 13.8.3 Takeda Pharmaceuticals Oral Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.8.4 Takeda Pharmaceuticals Main Business Overview 13.8.5 Takeda Pharmaceuticals Latest Developments 13.9 Novo Nordisk 13.9.1 Novo Nordisk Company Information 13.9.2 Novo Nordisk Oral Hypoglycemic Drugs Product Portfolios and Specifications 13.9.3 Novo Nordisk Oral Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.9.4 Novo Nordisk Main Business Overview 13.9.5 Novo Nordisk Latest Developments 13.10 Servier Laboratories 13.10.1 Servier Laboratories Company Information 13.10.2 Servier Laboratories Oral Hypoglycemic Drugs Product Portfolios and Specifications 13.10.3 Servier Laboratories Oral Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.10.4 Servier Laboratories Main Business Overview 13.10.5 Servier Laboratories Latest Developments 13.11 Boehringer Ingelheim 13.11.1 Boehringer Ingelheim Company Information 13.11.2 Boehringer Ingelheim Oral Hypoglycemic Drugs Product Portfolios and Specifications 13.11.3 Boehringer Ingelheim Oral Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.11.4 Boehringer Ingelheim Main Business Overview 13.11.5 Boehringer Ingelheim Latest Developments 13.12 Bristol-Myers Squibb 13.12.1 Bristol-Myers Squibb Company Information 13.12.2 Bristol-Myers Squibb Oral Hypoglycemic Drugs Product Portfolios and Specifications 13.12.3 Bristol-Myers Squibb Oral Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.12.4 Bristol-Myers Squibb Main Business Overview 13.12.5 Bristol-Myers Squibb Latest Developments 14 Research Findings and Conclusion